Ducharme is a contributor to TIME. Healthcare workers hold a tablet in front of a COVID-19 coronavirus patient during a video call with relatives at the Intensive Unit Care (ICU) of the Ramon y Cajal ...

Many patients suffer not only from respiratory symptoms due to their COVID-19 disease, but also from significantly reduced physical performance. A patent-protected tablet (CICR-NAM) developed at the ...

BENGALURU (Reuters) - Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency ...

The "Antacid Market Forecast to 2027 – COVID-19 Impact and Global Analysis By Dosage Form (Tablet, Liquid, Others); Drug Class (Proton pump inhibitors, H2 Antagonist, Acid neutralizers); Distribution ...